128 related articles for article (PubMed ID: 26162308)
1. Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.
Pio R; Agorreta J; Montuenga LM
J Thorac Cardiovasc Surg; 2015 Oct; 150(4):986-92.e1-11. PubMed ID: 26162308
[TBL] [Abstract][Full Text] [Related]
2. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
4. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
5. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
Raponi M; Zhang Y; Yu J; Chen G; Lee G; Taylor JM; Macdonald J; Thomas D; Moskaluk C; Wang Y; Beer DG
Cancer Res; 2006 Aug; 66(15):7466-72. PubMed ID: 16885343
[TBL] [Abstract][Full Text] [Related]
6. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
Wang K; Li Y; Wang J; Chen R; Li J
Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
[TBL] [Abstract][Full Text] [Related]
7. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.
Akagi I; Okayama H; Schetter AJ; Robles AI; Kohno T; Bowman ED; Kazandjian D; Welsh JA; Oue N; Saito M; Miyashita M; Uchida E; Takizawa T; Takenoshita S; Skaug V; Mollerup S; Haugen A; Yokota J; Harris CC
Cancer Res; 2013 Jul; 73(13):3821-32. PubMed ID: 23639940
[TBL] [Abstract][Full Text] [Related]
8. Lipase member H is a novel secreted protein selectively upregulated in human lung adenocarcinomas and bronchioloalveolar carcinomas.
Seki Y; Yoshida Y; Ishimine H; Shinozaki-Ushiku A; Ito Y; Sumitomo K; Nakajima J; Fukayama M; Michiue T; Asashima M; Kurisaki A
Biochem Biophys Res Commun; 2014 Jan; 443(4):1141-7. PubMed ID: 24380866
[TBL] [Abstract][Full Text] [Related]
9. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.
Park YY; Park ES; Kim SB; Kim SC; Sohn BH; Chu IS; Jeong W; Mills GB; Byers LA; Lee JS
PLoS One; 2012; 7(9):e44225. PubMed ID: 22970185
[TBL] [Abstract][Full Text] [Related]
14. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.
Kadara H; Behrens C; Yuan P; Solis L; Liu D; Gu X; Minna JD; Lee JJ; Kim E; Hong WK; Wistuba II; Lotan R
Clin Cancer Res; 2011 Mar; 17(6):1490-501. PubMed ID: 21163870
[TBL] [Abstract][Full Text] [Related]
15. Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma.
Chang YH; Chen CM; Chen HY; Yang PC
Sci Rep; 2015 Jun; 5():10979. PubMed ID: 26042604
[TBL] [Abstract][Full Text] [Related]
16. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
17. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
[TBL] [Abstract][Full Text] [Related]
18. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
[TBL] [Abstract][Full Text] [Related]
19. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
20. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
Seike M; Yanaihara N; Bowman ED; Zanetti KA; Budhu A; Kumamoto K; Mechanic LE; Matsumoto S; Yokota J; Shibata T; Sugimura H; Gemma A; Kudoh S; Wang XW; Harris CC
J Natl Cancer Inst; 2007 Aug; 99(16):1257-69. PubMed ID: 17686824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
